AIM: The aim of this study is to examine the frequency of increased risk for sarcopenia in patients with schizophrenia with regard to the acute phase and the remission phase. METHODS: The research was conducted in the period from March to May 2023 at the Clinic for Psychiatry. A total of 60 respondents participated, of which 30 were in the acute phase of schizophrenia, and 30 in the remission phase. The questionnaire consisted of two parts. One questionnaire was the SARC-F for assessing the risk of developing sarcopenia, and the other consisted of 11 questions related to sociodemographic data and 3 questions related to anthropometric measurements and the type of antipsychotics prescribed to the patients. RESULTS: In the conducted research, the hypothesis that subjects in the acute phase of the disease have a higher risk of developing sarcopenia was confirmed. It has not been confirmed that patients in the acute phase of schizophrenia use more typical antipsychotics. The hypothesis that patients in the acute phase of schizophrenia consume more tobacco compared to the phase of remission was also confirmed. The hypothesis that patients in the acute phase consume more alcohol compared to the remission phase was not confirmed. The expected result was that patients in the acute phase of the disease would have a higher risk for sarcopenia, which was ultimately proven. CONCLUSION: It has been proven that subjects in the acute phase of schizophrenia have a higher risk for sarcopenia. However, further research is needed regarding psychopharmacotherapy and its contribution to the development of sarcopenia, because patients in the acute phase have higher doses of antipsychotics compared to patients with schizophrenia in the remission phase.